PT  - JOURNAL ARTICLE
AU  - Montealegre, Maria Camila
AU  - Greenwood, Esther E.
AU  - Teichmann, Lisa
AU  - Nadimpalli, Maya L.
AU  - Caduff, Lea
AU  - Swarthout, Jenna M.
AU  - Nydegger, Tabea
AU  - Sultana, Sonia
AU  - Islam, Mohammad Aminul
AU  - Lanza, Val F.
AU  - Luby, Stephen P.
AU  - Pickering, Amy J.
AU  - Julian, Timothy R.
TI  - Drinking water chlorination impact on fecal carriage of extended-spectrum beta-lactamase-producing <em>Enterobacteriaceae</em> in Bangladeshi children in a double-blind, cluster-randomized controlled trial
AID  - 10.1101/2022.04.04.22273386
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.04.22273386
4099  - http://medrxiv.org/content/early/2022/04/08/2022.04.04.22273386.short
4100  - http://medrxiv.org/content/early/2022/04/08/2022.04.04.22273386.full
AB  - Background Water, sanitation, and hygiene (WASH) services have the potential to interrupt transmission of antimicrobial-resistant bacteria and reduce the need for antibiotics, thereby reducing selection for resistance. However, evidence of WASH impacts on antimicrobial resistance (AMR) is lacking.Methods We evaluated extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and ESBL-KESC (Klebsiella spp., Enterobacter spp., Serratia spp., and Citrobacter spp.) carriage in the feces of 479 Bangladeshi children under 5 years of age enrolled in a double-blind, cluster-randomized controlled trial of in-line drinking water chlorination in two low-income urban communities in Bangladesh. We additionally assessed the intervention’s impact on circulating beta-lactamase genes in fecal metagenomes and in genomes of fecal ESBL-E. coli isolates.Findings We detected ESBL-E. coli in 65% (n = 309) and ESBL-KESC in 12% (n = 56) of enrolled children. We observed no effect of the intervention on the prevalence of ESBL-E. coli (relative risk [95% confidence interval] = 0.98 [0.78, 1.23]) when controlling for study site and age. Although ESBL-KESC (0.76 [0.44, 1.29]) was lower among children in the intervention group, the relative risk was not significant. Concentrations of ESBL-E. coli (log10 CFU/g-wet) were on average [95% confidence interval] 0.13 [-0.16, 0.42] higher in the intervention group and ESBL-KESC (log10 CFU/g-wet) were 0.10 [-0.22, 0.02], lower in the intervention group, when controlling for study site and age. Furthermore, the distribution of ESBL-E.coli sequence types, type of beta-lactamase-encoding genes in ESBL-E. coli isolates, and the presence and relative abundance of beta-lactamase-encoding genes in children’s fecal metagenomes did not differ significantly between the intervention and control children.Interpretation One year of in-line drinking water chlorination in communities did not meaningfully impact the carriage of ESBL-E. coli among children in an area of high ESBL-E. coli carriage. While ESBL-KESC was at lower prevalence than ESBL-E. coli, in the intervention group, limited study power prevented a clear interpretation of treatment effect. Development and evaluation of effective interventions to reduce AMR carriage are needed to support calls for WASH embedded in current National and Global AMR Action Plans.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02606981Funding StatementFunding Source Statement: This work was funded by the Thrasher Research Fund (#14205). The funder had no role in data collection, data analysis, data interpretation, or writing of this report. MLN was supported by NIH award KL2TR002545 and the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR), a collaboration of Tufts Medical Center and the Tufts University Office of the Vice Provost for Research (OVPR) Research and Scholarship Strategic Plan (RSSP). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol for the original trial25 was approved by the International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b) scientific and ethical review committees (protocol number 14022) and the human subjects institutional review board at Stanford University (protocol number 30456). Within the original trial, informed written consent was obtained from all study participants as well as the owners of the water points enrolled. Consent included biospecimen collection for future unplanned analyses.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors